Literature DB >> 22682749

Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?

Katy Clarke1, Mojgan Taremi, Max Dahele, Marc Freeman, Sharon Fung, Kevin Franks, Andrea Bezjak, Anthony Brade, John Cho, Andrew Hope, Alexander Sun.   

Abstract

BACKGROUND AND
PURPOSE: Distant metastases are the dominant mode of failure after stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC). The primary study objective was to evaluate if the maximum standardized uptake value (SUV(max)) on pre-treatment FDG-PET/CT predicted clinical outcomes. Secondary objectives were to correlate 3-month post-SBRT SUV(max) and change in SUV(max) with outcomes.
MATERIALS AND METHODS: Consecutive patients with medically inoperable early-stage NSCLC and an FDG-PET/CT scan before (n=82) and 3 months after (n=62) SBRT.
RESULTS: Median follow up was 2 years. On univariate analysis baseline SUV(max) predicted for distant failure (p=0.0096), relapse free survival (RFS) (p=0.037) and local failure (p=0.044). On multivariate analysis baseline SUV(max) predicted for RFS (p=0.037). Baseline SUV(max) of above 5 was the most statistically significant cut off point for predicting distant failure (p=0.0002). Baseline SUV(max) ≥4.75 (median) was correlated with a higher risk of distant failure (p=0.012) and poorer RFS (p=0.04). Patients with a post-SBRT SUV(max) ≥2 and a reduction of <2.55 had a significantly higher rate of distant failure.
CONCLUSIONS: Pre-SBRT SUV(max) on FDG-PET/CT correlated most strongly with distant failure. A cut off of ≥5 was the most significant. Post-SBRT SUV(max) ≥2 and a reduction of <2.55 were associated with a higher risk of distant failure.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682749     DOI: 10.1016/j.radonc.2012.04.019

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  31 in total

Review 1.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

2.  A pilot study using kernelled support tensor machine for distant failure prediction in lung SBRT.

Authors:  Shulong Li; Ning Yang; Bin Li; Zhiguo Zhou; Hongxia Hao; Michael R Folkert; Puneeth Iyengar; Kenneth Westover; Hak Choy; Robert Timmerman; Steve Jiang; Jing Wang
Journal:  Med Image Anal       Date:  2018-09-15       Impact factor: 8.545

3.  Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control.

Authors:  Marguerite Tyran; Nathalie Charrier; Julien Darreon; Anne Madroszyk; Agnes Tallet; Naji Salem
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 4.  Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.

Authors:  Feng Liu; An Tai; Percy Lee; Tithi Biswas; George X Ding; Isaam El Naqa; Jimm Grimm; Andrew Jackson; Feng-Ming Spring Kong; Tamara LaCouture; Billy Loo; Moyed Miften; Timothy Solberg; X Allen Li
Journal:  Radiother Oncol       Date:  2016-11-18       Impact factor: 6.280

5.  Multi-objective radiomics model for predicting distant failure in lung SBRT.

Authors:  Zhiguo Zhou; Michael Folkert; Puneeth Iyengar; Kenneth Westover; Yuanyuan Zhang; Hak Choy; Robert Timmerman; Steve Jiang; Jing Wang
Journal:  Phys Med Biol       Date:  2017-05-08       Impact factor: 3.609

6.  Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters.

Authors:  Zhiguo Zhou; Michael Folkert; Nathan Cannon; Puneeth Iyengar; Kenneth Westover; Yuanyuan Zhang; Hak Choy; Robert Timmerman; Jingsheng Yan; Xian-J Xie; Steve Jiang; Jing Wang
Journal:  Radiother Oncol       Date:  2016-05-05       Impact factor: 6.280

7.  Evaluation of response after SBRT for liver tumors.

Authors:  Raphael Tétreau; Carmen Llacer; Olivier Riou; Emmanuel Deshayes
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-30

8.  FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.

Authors:  Zachary A Kohutek; Abraham J Wu; Zhigang Zhang; Amanda Foster; Shaun U Din; Ellen D Yorke; Robert Downey; Kenneth E Rosenzweig; Wolfgang A Weber; Andreas Rimner
Journal:  Lung Cancer       Date:  2015-05-28       Impact factor: 5.705

9.  Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy.

Authors:  Katsuyuki Shirai; Takanori Abe; Jun-Ichi Saitoh; Tatsuji Mizukami; Daisuke Irie; Yosuke Takakusagi; Shintaro Shiba; Naoko Okano; Takeshi Ebara; Tatsuya Ohno; Takashi Nakano
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

10.  Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy.

Authors:  Qian Li; Jongphil Kim; Yoganand Balagurunathan; Ying Liu; Kujtim Latifi; Olya Stringfield; Alberto Garcia; Eduardo G Moros; Thomas J Dilling; Matthew B Schabath; Zhaoxiang Ye; Robert J Gillies
Journal:  Med Phys       Date:  2017-06-24       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.